SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
2.210
-0.230 (-9.43%)
At close: Sep 3, 2025, 4:00 PM
2.290
+0.080 (3.62%)
Pre-market: Sep 4, 2025, 8:00 AM EDT
SciSparc Revenue
In the year 2024, SciSparc had annual revenue of $1.31M, down -54.64%. SciSparc had revenue of $466.00K in the half year ending December 31, 2024, a decrease of -65.40%.
Revenue (ttm)
$1.31M
Revenue Growth
-54.64%
P/S Ratio
0.47
Revenue / Employee
$653,000
Employees
2
Market Cap
1.18M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.31M | -1.57M | -54.64% |
Dec 31, 2023 | 2.88M | 1.53M | 113.73% |
Dec 31, 2022 | 1.35M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SPRC News
- 6 days ago - SciSparc: AutoMax's Shareholders Approve Merger with SciSparc - GlobeNewsWire
- 7 days ago - SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel - GlobeNewsWire
- 4 weeks ago - SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar - GlobeNewsWire
- 5 weeks ago - SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC - GlobeNewsWire
- 5 weeks ago - SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease - GlobeNewsWire
- 6 weeks ago - SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification - GlobeNewsWire
- 2 months ago - SciSparc Announces 1-for-21 Reverse Share Split - GlobeNewsWire
- 3 months ago - SciSparc Announces Publication of Japanese Patent Application - GlobeNewsWire